Cargando...
Evidence-based clinical standard for the diagnosis and treatment of invasive lung aspergillosis in the patient with oncohematologic disease
Author(s)
Universidad Nacional de Colombia
Diego Andrés Rodríguez Lugo
Universidad Nacional de Colombia
Martha Carolina Valderrama-Ríos
Universidad Nacional de Colombia
Ricardo Rabagliati
Pontificia Universidad Católica de Chile
Domênico Capone
Universidade Federal do Rio de Janeiro
Carlos Álvarez
Universidad Nacional de Colombia
Fabio Varón-Vega
Fundación Neumológica Colombiana
Laura Cristina Nócua-Báez
Universidad Nacional de Colombia
Cándida Díaz‐Brochero
Pontificia Universidad Javeriana
Leonardo Enciso-Olivera
Hospital Universitario Nacional de Colombia
Sonia Isabel Cuervo
Universidad Nacional de Colombia
Luis Thompson
Universidad del Desarrollo
Dora Corzo-León
University of Exeter
Luis E. Cuéllar
Federico Villarreal National University
Erika Paola Vergara
Hospital Universitario Nacional de Colombia
Fernando Riera
Universidad Nacional de Córdoba
Patricia Cornejo‐Juárez
Instituto Nacional de Cancerología
Rita Rojas
Beatriz L. Gómez
Universidad del Rosario
Adriana Marcela Celis Ramírez
Universidad de Los Andes
José Luis Sandoval‐Gutiérrez
Instituto Nacional de Enfermedades Respiratorias
Mauricio Sarmiento
Pontificia Universidad Católica de Chile
Diana Lorena Ochoa
Hospital Universitario Nacional de Colombia
Márcio Nucci
Universidade Federal do Rio de Janeiro
Date Issued
24 de febrero de 2025
Type
Article
Volume
29
Issue
2
Series/Report No.
The Brazilian Journal of Infectious Diseases
Start Page
104517
End Page
104517
ISSN
1413-8670
1678-4391
Abstract
Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.
Keywords